LALPATHLAB Stock Price and Chart — NSE:LALPATHLAB
NiveshIQ
NSE: LALPATHLAB · Healthcare
Dr. Lal Path Labs Ltd.
₹1,909.00▼ ₹7.70 (-0.40%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on LALPATHLAB. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Dr. Lal Path Labs Ltd.
Dr. Lal PathLabs Limited operates a network of laboratories providing pathological investigations in India and internationally, with a diverse range of services including bio-chemistry, hematology, and radiological investigations. The company's core business is driven by its laboratory services, which account for the majority of its revenue. Recent developments include the company's Q1 FY27 earnings, which delivered 19.1% revenue growth and a 31% EBITDA margin, driven by strong volume and innovation. Dr. Lal PathLabs has a strong competitive position in the Indian healthcare sector, with a large network of laboratories and a long history of operations dating back to 1949. The company's growth outlook is positive, with analysts expecting continued double-digit revenue and profit growth driv
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹2,226 Cr +10.40% | ₹2,462 Cr +10.60% | ₹2,763 Cr +12.20% |
| EBITDA Margin | 27.40% | 28.23% | 31.99% |
| Net Profit | ₹363.00 Cr +50.60% | ₹493.00 Cr +35.80% | ₹509.80 Cr +3.40% |
| EPS | ₹21.43 | ₹29.14 | ₹30.24 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
LALPATHLAB Outlook for the Week (August 31, 2026 – September 04, 2026)
Dr. Lal Path Labs Holds Gains Near ₹1,968: Diagnostics Leader Tests Key Levels - Stock Analysis
🔒
+ 3 more stories about Dr. Lal Path Labs Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹798 Cr, PAT ₹170 Cr, EPS ₹10.15, EBITDA margin 35.0%. Growth context: revenue QoQ +13.5%, PAT QoQ +29.0%. Street verdict: inline, revenue surprise +5.2%, PAT surprise -7.3%.
Test volumes, test mix, B2B/reference-lab traction, pricing discipline, and operating leverage remain the key forward dr...
FY26 (last completed FY): revenue ₹2, 763 Cr, PAT ₹510 Cr, EBITDA margin 32.0%, EPS ₹30.24. Year-on-year: revenue YoY +1...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for LALPATHLAB
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track LALPATHLAB alongside your other holdings
Unlock full LALPATHLAB research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Dr. Lal Path Labs Ltd.?
NiveshIQ detects active intelligence signals for Dr. Lal Path Labs Ltd. (LALPATHLAB) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Dr. Lal Path Labs Ltd.?
Dr. Lal Path Labs Ltd. operates in the Healthcare sector with a market capitalisation of ₹2,759,141.0L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.